Novartis AG at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mediterranean Transcript
Good morning. My name is Matthew Durdy. I'm the Chief Business Officer of the Cell and Gene Therapy Catapult. And we now have a panel presentation on commercialization.
Is that Dan? Sure. Sit here. Have you got a mic on? There's a microphone just coming for you then.
A couple of years ago, or quite a few years ago now, when we set off with the Cell and Gene Therapy Catapult with a mission to try and help the industry industrialize and create growth, we used to go and talk to people who are developing therapeutics and say, "You need to think about adoption. You need to think about pricing and reimbursement." And they'd look at us and go, "Yes, that's right, that's great." But what we're really concerned about is whether or not we're going to get a hearing with the regulator, whether or not the regulator is going to talk to us seriously. So it's fantastic to hear a presentation like we just heard, where ATMP is a part of the mainstream and part of adoption. It's also fantastic to hear in that presentation
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
